SR9009 is indexed as a chemical in Solt et al.’s Nature study of synthetic REV-ERB agonists; the paper reports preclinical circadian and metabolic observations in mice. The second citation supplies broader REV-ERBα mechanism context rather than direct evidence for every SR9009 claim. Neither paper establishes human efficacy, safety or an effective oral-use profile. The price list mixes eight Powder entries with one Liquid and one Injectable entry, while the dosage units, solution concentrations and vehicles are not stated. Treat those forms as separate specifications, not interchangeable labels.
| Class | SR9009 is indexed as a chemical in Solt et al.’s Nature study of synthetic REV-ERB agonists. |
| Chemical identity | Confirm the CAS reference, molecular formula, stereochemical or salt state when applicable, and batch identity by LC-MS and NMR or equivalent methods. |
| Powder entries | 1, 2, 5, 10, 25, 50, 100 and 200 / Powder. The price list does not state the dosage unit. |
| Other listed forms | 600 / Liquid and 640 / Injectable. Concentration, vehicle, dosage unit and packaging are not stated. |
| Assay and residuals | Verify assay or chromatographic purity, related substances, water and residual solvents for the allocated lot. |
| Formulation and handling | Confirm vehicle, concentration, light sensitivity, storage range and protocol compatibility separately for powder, liquid and injectable labels. |
Wholesale from $1.53
Published wholesale tiers apply when the order reaches 100+ total units; the tier is selected by quantity of each SKU. Smaller total orders are quoted separately.
| SKU / form | 10–24 units of this SKU | 25–49 units of this SKU | 50+ units of this SKU |
|---|---|---|---|
| 1 / Powder | $2.04 | $1.78 | $1.53 |
| 10 / Powder | $5.44 | $4.76 | $4.08 |
| 100 / Powder | $27.20 | $23.80 | $20.40 |
| 2 / Powder | $2.72 | $2.38 | $2.04 |
| 200 / Powder | $47.60 | $41.65 | $35.70 |
| 25 / Powder | $10.20 | $8.92 | $7.65 |
| 5 / Powder | $4.08 | $3.57 | $3.06 |
| 50 / Powder | $17.00 | $14.87 | $12.75 |
| 600 / Liquid | $49.98 | $43.74 | $37.49 |
| 640 / Injectable | $52.48 | $45.92 | $39.36 |
SR9009 should be qualified as a chemical research compound. The catalogue name, an HPLC percentage and a form label do not establish chemical identity, concentration or protocol compatibility.
Confirm the CAS reference, molecular formula, exact supplied state and batch identity using LC-MS and NMR or other suitable orthogonal methods.
Review the analytical method, assay or chromatographic purity, related substances, water and residual-solvent results. Distinguish a general specification from the allocated-lot result.
For liquid or injectable labels, require concentration, vehicle, excipients and container details. For powder, confirm solubility testing, storage and light-protection guidance for the planned protocol.
The cited papers report preclinical REV-ERB biology and synthetic-agonist experiments. They do not establish human use, oral bioavailability or the identity and performance of an independently supplied batch.
Solt et al. (2012). Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature. DOI: 10.1038/nature11030
Study scope: Mouse circadian-behavior and metabolic experiments plus the study's associated preclinical systems. The synthetic REV-ERB agonists, doses and formulations defined by the paper, including SR9009-related experiments.
What it supports: Supports describing preclinical circadian and metabolic observations for synthetic REV-ERB agonism.
Boundary: The paper does not establish human efficacy, safety, an effective oral regimen or supplier-batch equivalence.
Woldt et al. (2013). Rev-erb-α modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy. Nature Medicine. DOI: 10.1038/nm.3213
Study scope: Mouse and skeletal-muscle experimental systems used to study REV-ERBα, oxidative capacity, mitochondrial biogenesis and autophagy. Genetic and pharmacological conditions defined by the paper; this citation is mechanistic REV-ERBα context rather than direct evidence for every SR9009 claim.
What it supports: Supports only the broader mechanistic context connecting REV-ERBα with skeletal-muscle oxidative capacity and mitochondrial regulation.
Boundary: Do not treat this paper as direct proof of an SR9009 outcome. It does not establish human performance, therapeutic use or commercial-lot quality.
SR9009 is indexed as a chemical in Solt et al.’s Nature study of synthetic REV-ERB agonists. The paper reports preclinical circadian and metabolic observations in mice; it does not establish human efficacy, dosing or safety.
Solt et al. directly studied synthetic REV-ERB agonists, including SR9009-related experiments. Woldt et al. supplies broader REV-ERBα mechanism context, not direct proof for every SR9009 claim. Neither paper establishes human efficacy or safety.
The price list does not state dosage units, concentration, vehicle or excipients. A 600 / Liquid or 640 / Injectable entry cannot be treated as equivalent to a powder entry without those specifications.
Eight Powder entries are labelled 1, 2, 5, 10, 25, 50, 100 and 200. The list also contains 600 / Liquid and 640 / Injectable entries.
Powder, liquid and injectable rows are priced separately. Use the tier for the exact presentation and SKU quantity; published tiers apply when the order reaches 100+ total units.
Confirm chemical identity, the exact supplied state, assay or chromatographic purity, related substances, water, residual solvents and form-specific concentration, vehicle and handling instructions.